Chronic diffuse liver disease of non-viral etiology in the military

Abstract

The prevalence and structure of chronic diffuse liver diseases of non-viral etiology in 282 military men of the Western military district of different types of troops was studied. These diseases were detected in 164 (58,1%), of which non- alcoholic fatty liver disease was detected in 94 (33,3%) people, alcoholic liver disease – in 22 (7,8%), fatty liver disease of alcoholic metabolic etiology – in 48 (17%) of the examined. There were no cases of cholestatic, drug and autoimmune liver damage in the examined contingent. The proportion of favorable variant of chronic diffuse liver disease in the form of steatosis in persons suffering from non-alcoholic fatty liver disease was 80,9%, with alcohol-metabolic lesions – 75%, in the group of alcoholic liver disease – 100% of cases. The ratio of nosological forms in the structure of incidence of chronic diffuse liver diseases in the examined contingent was as follows: non-alcoholic steatosis – 46,3%, non-alcoholic steatohepatitis – 11%, alcoholic steatosis – 13,4%, alcoholic-metabolic steatosis – 22%, alcoholic-metabolic steatohepatitis – 7,3%. It was revealed that after 30 years the number of persons suffering from chronic diffuse liver diseases increased significantly (p<0,05) from 46,4 to 61,8%, mainly due to the increase in the incidence of fatty liver disease of alcoholic and metabolic etiology from 4,9 to 22,1%. The modulus of liver elasticity characterizing the degree of fibrosis in the group of non-alcoholic fatty liver disease and fatty liver disease of alcoholic metabolic etiology (5,8 kPa [5,2; 6,4] and 6,3 kPa [5,2; 7,4], respectively) was significantly (p<0,001) higher than in the control group (4,6 kPa [4,3; 4,9]). The controlled parameter of ultrasound attenuation reflecting the degree of steatosis in patients with non-alcoholic fatty liver disease and fatty liver disease of alcoholic metabolic etiology was higher than normal parameters (280 dB/m [268; 291], 303 dB/m [284; 322] and 233 dB/m, respectively) and significantly (p<0,001) differed from the values of the control group (223 dB/m [214; 233]). The degree of steatosis in the group of fatty liver disease of alcoholic metabolic etiology was significantly (p<0,05) higher than in the group of non-alcoholic fatty liver disease.

Keywords

chronic diffuse liver diseases of non-viral etiology / non-alcoholic fatty liver disease / alcoholic liver disease / fatty liver disease of alcoholic-metabolic etiology / steatosis / steatohepatitis / ultrasound / non-invasive assessment of fibrosis and steatosis of the liver / modulus of elasticity of the liver

References

[1] Балукова Е.В., Поражения печени различного генеза (токсического, лекарственного, дисметаболического): от этиологической гетерогенности к единой унифицированной терапии пациентов / Е.В. Балукова, Ю.П. Успенский, Ю.А. Фоминых // Русс. мед. журн. – 2018. – № 8. – С. 1–7.

[2] Буеверов, А.О. Эссенциальные фосфолипиды в комплексной терапии стеатогепатита смешанного генеза / А.О. Буеверов [и др.] // Клинические перспективы гастроэнтерологии, гепатологии. – 2008. – № 1. – С. 17–22.

[3] Ивашкин, В.Т. Диагностика и лечение неалкогольной жировой болезни печени: методические рекомендации / В.Т. Ивашкин, О.М. Драпкина, Ю.О. Шупелькова – М.: М-Вести, 2009. – 20 с.

[4] Ивашкин, В. Т. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно- поликлинической практики в Российской Федерации: результаты исследования DIREG 2 / В.Т. Ивашкин [и др.] // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2015. – № 6. – С. 31–41.

[5] Комова, А.Г. Принципы эффективной диагностики диффузных заболеваний печени на амбулаторном этапе / А.Г. Комова, М.В. Маевская, В.Т. Ивашкин // Росс. журн. гастроэнтерол. гепатол. колопроктол. – 2014. – № 5. – С. 36–41.

[6] Кравчук, Ю.А. Клинико-морфологические особенности стеатогепатита алкогольной и метаболической этиологии: автореф. дис. ... д-ра мед. наук / Ю. А. Кравчук. – СПб.: ВМА, 2016. – 33 c.

[7] Кучерявый, Ю.А. Хронический гепатит, цирроз печени и гепатоцеллюлярная карцинома – звенья одной цепи / Ю.А. Кучерявый, Н.Ю. Стукова, М.Л. Ахтаева // Клин. перспективы гастроэнтерол. гепатол. – 2012. – № 5. – С.3–11.

[8] Лазебник, Л.Б. Неалкогольная жировая болезнь печени: клиника, диагностика, лечение (рекомендации для терапевтов, 2-я версия) / Л.Б. Лазебник [и др.] // Экспер. и клин. гастроэнтерол. – 2017. – Т. 138, № 2. – С. 22–37.

[9] Chagas, A.L. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? / A.L. Chagas [et al.] // Braz. J. Med. Biol. Res. – 2009. – Vol.42. – P. 958–962.

[10] Dvorak, K. Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice – an exploratory case-control study / K. Drovak [et al.] // PLoS One. – 2014. – Vol. 9. – № 10. – e111551.

[11] EASL-EASD-EASO Clinical Practice Guideline for the management of non-alcoholic liver disease. European Association for the Study of the Liver (EASL) and European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) – Diabetologia – 2016. – Vol. 59. – P.1121–1140.

[12] Setiawan, V.W. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort / V.W. Setiawan // Hepatology – 2016. – Vol. 64. – P.1969–1977.

[13] Takuma, Y. Nonalcoholic steatohepatitis associated hepatocellular carcinoma: our case series and literature review / Y. Takuma, K. Nouso // Wld. J. Gastroenterol. – 2010. – Vol. 16. – P.1436–1441.

[14] Waly Raphael, S. Hepatocellular carcinoma: focus on different aspects of management / S. Waly Raphael, Z. Yangde, C. Yuxiang // ISRN Oncol. – 2012. – P. 1–12.

[15] Younossi, Z.M. Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes / Z.M. Younossi [et al.] // Hepatology – 2016. – Vol. 63. – P. 73–84.

RIGHTS & PERMISSIONS

- -.